Ind Swift Laboratories To Invest ₹400 Million In Samba Facility Upgrade

Ind Swift Laboratories is stepping up its global ambitions with a major capital investment in its Samba facility. The ₹400 million upgrade will modernize the plant to meet stringent international benchmarks, including EU-GMP and PIC/S standards.  

The enhanced facility will focus on producing high-quality dosage forms such as tablets, capsules, syrups, and ointments, positioning the company to expand exports to Europe, the UK, Australia, Canada, and South Africa. The upgrade is expected to be completed within 8–12 months, with EU-GMP approval targeted shortly thereafter.  

Company officials emphasized that the investment reflects Ind Swift’s commitment to innovation, compliance, and global competitiveness. By strengthening its manufacturing base, the firm aims to capture new opportunities in regulated markets while supporting India’s reputation as a reliable pharmaceutical hub.  

Key Highlights  

• ₹400 million investment in Samba facility upgrade  
• Focus on aligning with EU-GMP and PIC/S standards  
• Production of tablets, capsules, syrups, and ointments  
• Exports targeted to Europe, UK, Australia, Canada, South Africa  
• Upgrade completion expected within 8–12 months  

Sources: Business Upturn, Ind Swift Group, Expansion Report